The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Probiotics may leads to higher disease improvement (based on clinical scores) compared with placebo (low certainty).
It is very uncertain whether probiotics changes minor adverse events compared with placebo (very low certainty).
It is very uncertain whether probiotics changes serious adverse events compared with placebo (very low certainty).
Probiotics showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).
Probiotics showed no clear difference in clinical remission compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (low certainty).
It is very uncertain whether probiotics changes minor adverse events compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (very low certainty).
It is very uncertain whether probiotics changes serious adverse events compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (very low certainty).
It is very uncertain whether probiotics changes withdrawal due to adverse events compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (very low certainty).
It is very uncertain whether probiotics changes clinical relapse (12 to 52 weeks) compared with placebo (very low certainty).
It is very uncertain whether probiotics changes withdrawal due to adverse events (52 weeks) compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) changes clinical relapse (12 to 52 weeks) compared with 5‐ASA (mesalazine) (very low certainty).
Probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) showed no clear difference in maintenance of clinical remission (24 to 52 weeks) compared with 5‐ASA (mesalazine) (low certainty).
The review found no eligible studies for this question.
It is very uncertain whether probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) changes withdrawal due to adverse events (12 to 52 weeks) compared with 5‐ASA (mesalazine) (very low certainty).
The review found no eligible studies for this question.